BiotechTube
EntroGen

EntroGen

Woodland Hills, United States· Est.
entrogen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8M

Overview

EntroGen is a privately held, commercial-stage diagnostics company founded in 2008 and headquartered in Woodland Hills, California. The company has established a commercial footprint with its FDA-approved companion diagnostic for KRAS/NRAS mutations in colorectal cancer and is expanding its portfolio with RUO kits for minimal residual disease (MRD) and microsatellite instability (MSI). EntroGen's strategy centers on providing end-to-end, automated molecular diagnostic solutions to support personalized treatment decisions in oncology.

Oncology

Technology Platform

Integrated real-time PCR-based diagnostic platform encompassing automated sample preparation (Benchbot®), proprietary assay reagents, and genomic interpretation software for end-to-end workflow in oncology testing.

Funding History

3
Total raised:$2.8M
Seed$2.5M
Grant$145K
Grant$141K

Opportunities

The growing adoption of immunotherapy, where MSI status is a key biomarker, presents a major expansion opportunity beyond its core colorectal cancer focus.
Furthermore, the trend towards automated, integrated lab solutions allows EntroGen to differentiate itself and capture market share from labs seeking to improve efficiency and standardization.

Risk Factors

Intense competition from large diagnostic conglomerates and other niche players, along with the potential technological disruption from next-generation sequencing (NGS) panels, poses significant market risks.
Regulatory hurdles and securing favorable reimbursement rates for new tests remain persistent challenges to commercial growth.

Competitive Landscape

EntroGen competes in a crowded field with large, diversified diagnostics companies (e.g., Roche, Qiagen, Thermo Fisher) that offer broad portfolios and automation platforms, as well as other focused molecular diagnostic firms. Its competitive edge relies on its specialized focus in oncology, its FDA-approved companion diagnostic status, and its integrated hardware-software-reagent approach.

More companies in Diagnostics & Precision Medicine →More companies in United States →